Showing 541 - 560 results of 6,168 for search '"elevation"', query time: 0.07s Refine Results
  1. 541

    Elevated Plasma Soluble Triggering Receptor Expressed on Myeloid Cells-1 Level in Patients with Acute Coronary Syndrome (ACS): A Biomarker of Disease Severity and Outcome by Shachaf Shiber, Vitaly Kliminski, Katia Orvin, Iftach Sagy, Mordehay Vaturi, Ran Kornowski, Michael Drescher, Yair Molad

    Published 2021-01-01
    “…Plasma sTREM-1 levels are significantly elevated in patients with ACS and might serve as a biomarker differentiating ACS from NSCP in the ED as well as an inflammatory biomarker for coronary artery disease severity and outcome.…”
    Get full text
    Article
  2. 542

    Visfatin Related to the Severity of Non-ST-Segment Elevation Acute Coronary Syndrome: A Retrospective Study of 164 Patients at a Tertiary Chest Pain Center by Meifan Zheng, Zhongwei Wu, Chaoquan Liu, Fei Xiao

    Published 2024-01-01
    “…Acute coronary syndrome (ACS) poses a pervasive threat to individuals grappling with cardiovascular afflictions, manifesting as unstable angina, non-ST-segment elevation myocardial infarction (NSTEMI), ST-segment elevation myocardial infarction (STEMI), or sudden cardiac death, depending on vascular obstruction’s extent and location. …”
    Get full text
    Article
  3. 543
  4. 544
  5. 545
  6. 546
  7. 547
  8. 548

    Hemolysis, Elevated Liver Enzymes, and Low Platelets, Severe Fetal Growth Restriction, Postpartum Subarachnoid Hemorrhage, and Craniotomy: A Rare Case Report and Systematic Review by Shadi Rezai, Justin Faye, Alexander Hughes, Mon-Lai Cheung, Joel R. Cohen, Judy A. Kaia, Paul N. Fuller, Cassandra E. Henderson

    Published 2017-01-01
    “…Introduction. Hemolysis, elevated liver enzymes, and low platelets (HELLP) syndrome is a relatively uncommon but traumatic condition occurring in the later stage of pregnancy as a complication of severe preeclampsia or eclampsia. …”
    Get full text
    Article
  9. 549
  10. 550

    Change in Growth Differentiation Factor 15, but Not C-Reactive Protein, Independently Predicts Major Cardiac Events in Patients with Non-ST Elevation Acute Coronary Syndrome by Alberto Dominguez-Rodriguez, Pedro Abreu-Gonzalez, Idaira F. Hernandez-Baldomero, Pablo Avanzas, Francisco Bosa-Ojeda

    Published 2014-01-01
    “…The aims of our study are: (a) to describe the changes in hsCRP and GDF-15 levels over a period of time and after an episode of non-ST-segment elevation acute coronary syndrome (NSTE-ACS) and (b) to examine whether the rate of change in hsCRP and GDF-15 after the acute event is associated with long-term major cardiovascular adverse events (MACE). …”
    Get full text
    Article
  11. 551
  12. 552
  13. 553
  14. 554

    Short- and long-term survival after ST-elevation myocardial infarction treated with pharmacoinvasive versus primary percutaneous coronary intervention strategy: a prospective cohort study by Sigrun Halvorsen, Jon Michael Gran, Kristin Kvakkestad

    Published 2022-07-01
    “…Objective Compare survival in patients with ST-elevation myocardial infarction (STEMI) treated with a pharmacoinvasive (PI) or primary percutaneous coronary intervention (pPCI) strategy based on estimated time to PCI.Design Prospective observational cohort study. …”
    Get full text
    Article
  15. 555
  16. 556

    A Nomogram Based on Apelin-12 for the Prediction of Major Adverse Cardiovascular Events after Percutaneous Coronary Intervention among Patients with ST-Segment Elevation Myocardial Infarction by Enfa Zhao, Hang Xie, Yushun Zhang

    Published 2020-01-01
    “…This study aimed to establish a clinical prognostic nomogram for predicting major adverse cardiovascular events (MACEs) after primary percutaneous coronary intervention (PCI) among patients with ST-segment elevation myocardial infarction (STEMI). Methods. Information on 464 patients with STEMI who performed PCI procedures was included. …”
    Get full text
    Article
  17. 557

    Evaluate Short-Term Outcomes of abciximab in ST-Segment Elevation Myocardial Infarction Patients Undergoing Percutaneous Coronary Intervention: A Meta-Analysis of Randomized Clinical Trials by Nan Bai, Ying Niu, Ying Ma, Yao-Sheng Shang, Peng-Yu Zhong, Zhi-Lu Wang

    Published 2022-01-01
    “…This meta-analysis was to verify the short-time efficacy and safety of abciximab in patients with ST-segment elevation myocardial infarction (STEMI) undergoing percutaneous coronary intervention (PCI). …”
    Get full text
    Article
  18. 558

    Diabetic ketoacidosis and hyperglycemic hyperosmolar state are associated with higher in-hospital mortality and morbidity in diabetes patients hospitalized with ST-elevation myocardial infarction, but not within 30 days of readmission. by Turki Almutairi, Soha Dargham, Amin Jayyousi, Jassim Al Suwaidi, Charbel Abi Khalil

    Published 2025-01-01
    “…Our study aimed to explore the impact of diabetic ketoacidosis (DKA) and hyperglycemic hyperosmolar state (HHS), both severe hyperglycemic conditions, on cardiovascular outcomes in patients with T2D admitted for ST-elevation myocardial infarction (STEMI).<h4>Methods</h4>We used the National Readmission Database (2016-2019) to extract patients with T2DM and STEMI at baseline. …”
    Get full text
    Article
  19. 559
  20. 560